From idea to product: drug development

drapeau-france-icone-7111-32

 

There are over 25 million cancer patients worldwide, with approx. 9 million deaths from cancer every year. In spite of much progress, the response rate for chemotherapy remains low (only 20 to 60%) and relapse after therapy is frequent. Unfortunately, relapsed tumors are usually resistant to the chemotherapy agent previously used. Thus, there is an urgent unmet need for discovery of new innovative therapies.

Molecules originating from the ocean constitute an underexplored source of drugs, in particular of anticancer therapeutics.

CORAL BIOME participates in the global anticancer innovation effort and devotes its research and development (R&D) activity to applications of these marine molecules for anticancer therapy. The aim is to characterize drug candidates that can be taken up by the pharmaceutical industry and developed in order to eventually offer new therapies to patients.

The development of an anticancer drug is long and complex and may span 10 to 15 years. It is necessary to conduct many studies and to pass many regulatory steps in order to move new potential drugs from the R&D stage to the first clinical trials. Only after successive successful trials can a new drug be approved for release and made available to patients (for more details, see here).

The molecules studied by CORAL BIOME are currently in the discovery phase and at early preclinical stage (laboratory and animal studies, for more details, see here). In other words the efficacy and safety of our molecules is being evaluated and requires additional regulatory steps before they can be given to patients in the framework of clinical trials.

Thus the therapies we are developing are unfortunately not yet available to patients. We do our utmost to accelerate their development.

In the meantime we recommend that patients and relatives searching for innovative therapies consult the NIH’s clinical trials registry (see here) to obtain information on the latest available innovations; they should discuss this with their MD (oncologist).